MNPR
Monopar Therapeutics Inc.
There isn't enough reported data to score MNPR yet.
MNPR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
MNPR's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
MNPR PE Valuation
MNPR has no meaningful PE right now: it lost money over the past year.
MNPR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect MNPR's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
MNPR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.50 | +$1.45 |
| Q2 2026 | -$2.26 | +$1.58 |
| Q1 2026 | -$1.99 | +$2.00 |
| Q4 2025 | -$1.91 | +$2.20 |
| Q3 2025 | -$3.95 | -$1.94 |
| Q2 2025 | -$3.84 | -$1.50 |
| Q1 2025 | -$3.99 | -$1.35 |
| Q4 2024 | -$4.11 | -$1.05 |
MNPR is still losing money, but less than at its worst: $2.50 per share over the past year, against $4.11 at its worst in late 2022.
MNPR Quarterly Revenue
MNPR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.2M | -$4.1M |
| Q2 2026 | -$3.2M | -$2.2M |
| Q1 2026 | -$3.5M | +$2.2M |
| Q4 2025 | -$3.4M | -$1.4M |
| Q3 2025 | -$2.1M | -$1M |
| Q2 2025 | -$1.1M | +$599.4K |
| Q1 2025 | -$5.7M | -$4M |
| Q4 2024 | -$2M | -$452.5K |
MNPR has burned cash in almost every quarter: −$16M over the past year, against −$11M the year before.
MNPR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +18.9K shares |
| 1 year | +20% | +1.4M shares |
| 3 years | +224% | +5.9M shares |
| 5 years | +253% | +6.1M shares |
| Available history | +359% | +6.7M shares |
MNPR has 9M diluted shares, up 20% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
MNPR Net Leverage
MNPR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MNPR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.2 | Neutral |
| Stochastic | 8.8 | Oversold |
MNPR's weekly RSI is 42 (neutral) and its Stochastic is 9 (oversold).
MNPR PE vs Healthcare Sector
MNPR has no meaningful PE right now: it lost money over the past year.
MNPR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $74.6 | 2.5% below |
| 20 week MA | $95.3 | 24% below |
| 50 week MA | $75.7 | 3.9% below |
| 100 week MA | $61.2 | 19% above |
| 200 week MA | $33.6 | 116% above |
MNPR has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 116% above its 200-week average.
MNPR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2019 | $135.0 | $99.0 | -27% |
| 2020 | $99.0 | $37.5 | -62% |
| 2021 | $37.5 | $16.7 | -55% |
| 2022 | $16.7 | $12.3 | -26% |
| 2023 | $12.3 | $1.70 | -86% |
| 2024 | $1.70 | $24.5 | +1343% |
| 2025 | $24.5 | $68.8 | +180% |
| 2026 YTD | $68.8 | $72.7 | +5.7% |
MNPR's yearly returns have swung widely, from +1343% in 2024 to −86% in 2023. It's up 5.7% so far in 2026.